Articles written by: Catherine Smith

Anixa Biosciences Inc. (ANIX) and Soleno Therapeutics Inc. (NASDAQ:SLNO) Contrasting side by side

Anixa Biosciences Inc. (NASDAQ:ANIX) and Soleno Therapeutics Inc. (NASDAQ:SLNO) are two firms in the Medical Laboratories & Research that compete against each other. Below is a comparison of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per […]

Quanterix Corporation (QTRX)’s Financial Results Comparing With Allakos Inc. (NASDAQ:ALLK)

Quanterix Corporation (NASDAQ:QTRX) and Allakos Inc. (NASDAQ:ALLK) compete against each other in the Biotechnology sector. We will compare them and contrast their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation. Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quanterix Corporation 27 14.24 […]

Aduro BioTech Inc. (ADRO)’s Financial Results Comparing With Sorrento Therapeutics Inc. (NASDAQ:SRNE)

We are contrasting Aduro BioTech Inc. (NASDAQ:ADRO) and Sorrento Therapeutics Inc. (NASDAQ:SRNE) on their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation. They both are Biotechnology companies, competing one another. Earnings & Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aduro BioTech Inc. 2 […]

Silvercrest Asset Management Group Inc. (SAMG)’s Financial Results Comparing With Rand Capital Corporation (NASDAQ:RAND)

We are contrasting Silvercrest Asset Management Group Inc. (NASDAQ:SAMG) and Rand Capital Corporation (NASDAQ:RAND) on their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation. They both are Asset Management companies, competing one another. Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silvercrest […]

Reviewing New Mountain Finance Corporation (NMFC)’s and Nuveen Intermediate Duration Municipal Term Fund (NYSE:NID)’s results

New Mountain Finance Corporation (NYSE:NMFC) and Nuveen Intermediate Duration Municipal Term Fund (NYSE:NID) compete against each other in the Asset Management sector. We will contrast them and contrast their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation. Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per […]

Can-Fite BioPharma Ltd. (CANF) and Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) Contrasting side by side

Both Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) and Y-mAbs Therapeutics Inc. (NASDAQ:YMAB) are Biotechnology companies, competing one another. We will contrast their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation. Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Can-Fite BioPharma Ltd. 6 2.21 N/A […]

Reviewing Badger Meter Inc. (BMI)’s and Schmitt Industries Inc. (NASDAQ:SMIT)’s results

We are contrasting Badger Meter Inc. (NYSE:BMI) and Schmitt Industries Inc. (NASDAQ:SMIT) on their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership. They both are Scientific & Technical Instruments companies, competing one another. Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Badger […]

Comparison of Onconova Therapeutics Inc. (ONTX) and Novelion Therapeutics Inc. (NASDAQ:NVLN)

As Biotechnology companies, Onconova Therapeutics Inc. (NASDAQ:ONTX) and Novelion Therapeutics Inc. (NASDAQ:NVLN) are our subject to contrast. And more specifically their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation. Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Onconova Therapeutics Inc. 3 4.01 […]